ClinicalTrials.gg
CompletedNCT01112267Updated Jul 24, 2013Results posted

An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain

A Phase 3 interventional study of Tramadol HCl/acetaminophen Extended Release and Placebo in Low Back Pain, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-24.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing acetaminophen in Low Back Pain — none open to participants now, none under way, none of them phase 3. Acetaminophen · Low Back Pain.

Enrollment
2nd of 10
248 · median 120
Started
2009
the only one that year
Phase 3
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Janssen Korea, Ltd., Korea

Among the 10 studies testing acetaminophen in Low Back Pain, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 4 in phase 3, and was the 3rd registered.

Low Back Pain

2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

None of the 10 studies testing acetaminophen in Low Back Pain is open now. The open studies under Low Back Pain, anywhere →

Where they have run

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing acetaminophen in Low Back Pain as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of extended release (ER) tramadol hydrochloride (HCl)/acetaminophen compared with placebo in participants with chronic (lasting a long time) low-back pain.

Read the detailed description

This is a double blind (a medical research study in which neither the researchers nor the participants know what treatment the participants is receiving), randomized (study drug is assigned by chance), placebo-controlled, parallel group (a medical research study comparing the response in 2 or more groups of participants receiving different interventions [treatments]) and up-titration study in participants with chronic low back pain. The study will consist of 6 visits (Day -7 to Day -1 [Visit 1], Day 1 [Visit 2], Day 3 [telephone visit], Day 8 [Visit 3], Day 15 [Visit 4] and Day 29 [Visit 5]) and 2 phases: a screening phase and treatment phase. Screening phase will be of 7 days during which, participants will receive stable dose of non-steroidal anti-inflammatory drugs (NSAIDS) or COX-2 selective inhibitors (NSAID that specifically inhibits an enzyme known as cyclooxygenase-2) for pain therapy. On the basis of average pain intensity over the last 48 hours which will be measured at baseline (at the end of screening period), participants will enter the treatment phase. Treatment phase will be of 28 days which includes 7-days of dose titration period. In treatment phase all participants will be randomly assigned to 1 of 2 possible treatments: tramadol HCl 75 milligram (mg)/acetaminophen 650 mg ER tablet treatment or the equivalent placebo (an inactive substance) treatment until study completion, Day 29. Participants will receive 1 tablet of tramadol HCl/acetaminophen ER or its equivalent placebo, once daily for 3 days. After the first 3 days, the participants will receive a telephone inquiry monitoring the occurrence of adverse events and will be given additional administration instructions for the next 4 days (1 tablet twice daily for 4 days). From Day 7, participants will receive 1 or 2 tablets twice a day depending on the degree of pain relief required. Participants will visit the center on the Day 8 (Visit 3), Day 15 (Visit 4), and Day 29 (Visit 5) after starting study drug. The efficacy will be assessed by measuring extent of reduction in pain intensity on a Visual Analog Scale (VAS). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Low Back Pain

Browse trials for

Keywords

  • Chronic low back pain
  • Tramadol Hydrochloride (HCl)
  • acetaminophen
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with low back pain at least 3 months before the screening or
  • Participants who have taken a stable dose of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (drugs used for reducing inflammation and pain ) or Cyclo-Oxygenase 2 (COX-2) selective inhibitors (an anti-inflammatory drug that fights pain) from 7 days before product administration, and could maintain the same dose during the period of the study
  • Participants whose average pain intensity is more than or equal to 4.0 centimeters on Visual Analog Scale over the last 48 hours after the completion of screening
  • or surgically sterile or abstinent women or practicing a highly effective method of
  • Women with must have negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Participants who have taken tramadol or tramadol HCl or acetaminophen, or narcotic (strong habit-forming drug that stops pain and depresses the central nervous system) analgesic tablet within 30 days before product administration
  • Participants who have taken acetaminophen tablet within 7 days before investigational product administration
  • Participants with tumor or infection in meninges or spinal cord
  • Participants who have fibromyalgia (neurosensory disorder characterized by muscle pain, joint stiffness, and fatigue), reflex sympathetic dystrophy (feeling of pain associated with evidence of minor nerve injury) or causalgia (persistent, severe burning sensation of the skin), acute spinal cord compression, acute nerve root compression, severe lower extremity weakness or numbness, regional pain syndrome, meningitis (inflammation of the meninges), diskitis (nonbacterial inflammation of an intervertebral disk or disk space), back pain because of secondary infection or tumor, or pain caused by a confirmed or suspected neoplasm
  • Participants who have taken analgesic (including local agents or anesthetics), sedative-hypnotic (e.g., diazepam), or muscle relaxant other than a stable dose of NSAIDs or COX-2 selective inhibitors within 5 times the half-life of the concerned agent before investigational product administration
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Tramadol Hydrochloride (HCl)/acetaminophen

    Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.

    Drug: Tramadol HCl/acetaminophen Extended Release

  • Placebo comparator
    Placebo

    Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.

    Drug: Placebo

Interventions

  • DrugTramadol HCl/acetaminophen Extended Release

    Drug pages: Tramadol · Acetaminophen

    Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7

    Also known as: Ultracet Extended Relaese

  • DrugPlacebo

    Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7

  • DrugTramadol HCl/acetaminophen Extended Release

    Drug pages: Tramadol · Acetaminophen

    Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28

    Also known as: Ultracet Extended Relaese

  • DrugPlacebo

    Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Reduction in Pain Intensity

    The percentage of participants with extent of reduction in pain intensity greater than or equal to 30 percent was reported. Pain intensity change rate was calculated by Visual Analog Scale (VAS) score at baseline minus VAS score at Day 29 divided by VAS score at Baseline. VAS is a 10 centimeter (cm) scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.

    Time frame: Baseline up to Day 29

  2. Change From Baseline in Pain Intensity at Day 29

    Change in pain intensity experienced by participants over the last 48 hours was measured on Day 29 against Baseline with VAS. VAS is a 10 cm scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.

    Time frame: Baseline and Day 29

Secondary outcomes

  1. Percentage of Participants With Pain Relief

    Pain relief was measured in 6 stages to assess the participant's pain relief. Extent of pain relief was measured on a scale ranging from 4 to -1, where 4=complete disappearance, 3=fair relief, 2=moderate relief, 1=slight relief, 0=no change and -1=pain worsening. Relief more than 'slight relief (1)' was considered as pain relief success.

    Time frame: Day 8, Day 15 and Day 29

  2. Change From Baseline in Short Form (SF)-36 Score at Day 29

    The quality of life of participants was evaluated by SF-36 Korean version questionnaire. It is composed of 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Participants answered to the questionnaire of 36 questions; and physical, social, and psychological health status were assessed. It ranges 0 to 100, and higher score indicates better quality of life, But in "Reported (Rptd.) Health Transition" domain higher score indicates worse quality of life.

    Time frame: Baseline and Day 29

  3. Change From Baseline in Oswestry Disability Index (ODI) Korean Version Score at Day 29

    The ODI Korean version was used to assess the participant's functionality. The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). Total score is the sum of score obtained in each section and ranges from 0 to 50. A higher score represents greater disability.

    Time frame: Baseline and Day 29

  4. Percentage of Participants With Investigator's Global Assessment on Investigational Product

    Global assessment on investigational product was done by investigator on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.

    Time frame: Day 29

  5. Percentage of Participants With Participants' Global Assessment on Investigational Product

    Global assessment on investigational product was done by participants on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.

    Time frame: Day 29

07

Results

Posted Jul 24, 2013

Participant flow

Participant flow — Overall Study
MilestoneTramadol HCl/AcetaminophenPlacebo
Started126122
Treated125120
Completed92104
Not completed3418
Withdrew: Adverse event246
Withdrew: Withdrawal by subject35
Withdrew: Protocol violation53
Withdrew: Participants not compliant12
Withdrew: Participants not receive any study drug12

Outcome measures

PrimaryPercentage of Participants With Reduction in Pain Intensity

The percentage of participants with extent of reduction in pain intensity greater than or equal to 30 percent was reported. Pain intensity change rate was calculated by Visual Analog Scale (VAS) score at baseline minus VAS score at Day 29 divided by VAS score at Baseline. VAS is a 10 centimeter (cm) scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.

Time frame:
Baseline up to Day 29
Reported as:
Number · Percentage of Participants
Percentage of Participants With Reduction in Pain Intensity
Percentage of ParticipantsTramadol HCl/AcetaminophenPlacebo
Percentage of Participants With Reduction in Pain Intensity57.65 (47.14 to 68.15)41.11 (30.95 to 51.28)
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Cochran-Mantel-Haenszel · p = 0.0367p-value for percentage of participants with reduction in pain intensity was calculated for tramadol HCl/acetaminophen and placebo groups
PrimaryChange From Baseline in Pain Intensity at Day 29

Change in pain intensity experienced by participants over the last 48 hours was measured on Day 29 against Baseline with VAS. VAS is a 10 cm scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.

Time frame:
Baseline and Day 29
Reported as:
Mean · Unit on a scale
Change From Baseline in Pain Intensity at Day 29
Unit on a scaleTramadol HCl/AcetaminophenPlacebo
Baseline6.334 ± 1.3836.000 ± 1.331
Change at Day 292.299 ± 1.7641.549 ± 1.578
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Mann-Whitney U test · p = 0.0095 (p-value for change in reduction in pain intensity at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups)
SecondaryPercentage of Participants With Pain Relief

Pain relief was measured in 6 stages to assess the participant's pain relief. Extent of pain relief was measured on a scale ranging from 4 to -1, where 4=complete disappearance, 3=fair relief, 2=moderate relief, 1=slight relief, 0=no change and -1=pain worsening. Relief more than 'slight relief (1)' was considered as pain relief success.

Time frame:
Day 8, Day 15 and Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief
Percentage of participantsTramadol HCl/AcetaminophenPlacebo
Day 8: Slight relief (n=82,88)70.73 (60.88 to 80.58)53.41 (42.99 to 63.83)
Day 15: Slight relief (n=85,89)82.35 (74.25 to 90.46)65.17 (55.27 to 75.07)
Day 29, Slight relief (85,89)81.18 (72.87 to 89.49)77.53 (68.86 to 86.20)
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Chi-squared · p = 0.0202 (p-value for percentage of participants with pain relief at Day 8 was calculated for tramadol HCl/acetaminophen and placebo groups)
  • Tramadol HCl/Acetaminophen vs Placebo · Chi-squared · p = 0.0102 (p-value for percentage of participants with pain relief at Day 15 was calculated for tramadol HCl/acetaminophen and placebo groups)
  • Tramadol HCl/Acetaminophen vs Placebo · Chi-squared · p = 0.4652 (p-value for percentage of participants with pain relief at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups)
SecondaryChange From Baseline in Short Form (SF)-36 Score at Day 29

The quality of life of participants was evaluated by SF-36 Korean version questionnaire. It is composed of 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Participants answered to the questionnaire of 36 questions; and physical, social, and psychological health status were assessed. It ranges 0 to 100, and higher score indicates better quality of life, But in "Reported (Rptd.) Health Transition" domain higher score indicates worse quality of life.

Time frame:
Baseline and Day 29
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form (SF)-36 Score at Day 29
Unit on a scaleTramadol HCl/AcetaminophenPlacebo
Baseline: Physical functioning46.71 ± 20.7147.94 ± 20.80
Change at Day 29: Physical functioning (n=83,87)9.82 ± 18.356.67 ± 15.99
Baseline: Role physical44.93 ± 24.1849.51 ± 26.17
Change at Day 29: Role Physical (n=83,87)16.04 ± 23.898.69 ± 22.62
Baseline: Bodily pain34.66 ± 14.4635.99 ± 13.89
Change at Day 29: Bodily pain (n=83,87)19.39 ± 18.9917.69 ± 14.84
Baseline: General health43.56 ± 17.9248.11 ± 17.05
Change at Day 29: General health (n=83,87)7.36 ± 14.412.77 ± 12.58
Baseline: Vitality38.82 ± 19.9342.71 ± 17.83
Change at Day 29: Vitality (n=83,87)11.14 ± 20.555.82 ± 18.94
Baseline: Social functioning64.26 ± 22.5964.58 ± 26.98
Change at Day 29: Social functioning (n=83,87)11.75 ± 25.706.61 ± 20.60
Baseline: Role emotional61.76 ± 27.4161.57 ± 29.34
Change at Day 29: Role emotional (n=83,87)8.13 ± 28.937.47 ± 28.25
Baseline: Mental Health61.06 ± 19.0360.56 ± 19.34
Change at Day 29: Mental Health (n=83,87)20.48 ± 23.2018.39 ± 24.61
Baseline: Rptd. health transition65.00 ± 24.7663.61 ± 20.92
Change at Day 29: Rptd. health transition(n=83,87)-18.07 ± 25.99-6.90 ± 30.19
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.3524 (p-value for change from Baseline in physical conditioning at Day 29 was calculated using for tramadol HCl/acetaminophen and placebo groups)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0224 (p-value for change from Baseline in role physical at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5712 (p-value for change from Baseline in bodily pain at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0395 (p-value for change from Baseline in general health at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0524 (p-value for change from Baseline in vitality at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.115 (p-value for change from Baseline in social functioning at Day 29 was calculated using for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.7788 (p-value for change from Baseline in role emotional at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.7776 (p-value for change from Baseline in mental health at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0047 (p-value for change from Baseline in Reptd. health transition at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
SecondaryChange From Baseline in Oswestry Disability Index (ODI) Korean Version Score at Day 29

The ODI Korean version was used to assess the participant's functionality. The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). Total score is the sum of score obtained in each section and ranges from 0 to 50. A higher score represents greater disability.

Time frame:
Baseline and Day 29
Reported as:
Mean · Unit on a scale
Change From Baseline in Oswestry Disability Index (ODI) Korean Version Score at Day 29
Unit on a scaleTramadol HCl/AcetaminophenPlacebo
Baseline39.626 ± 12.23938.126 ± 13.518
Change at Day 29 (n=87,83)11.216 ± 11.8567.178 ± 13.879
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0527 (p-value for change from Baseline in ODI- Korean version at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
SecondaryPercentage of Participants With Investigator's Global Assessment on Investigational Product

Global assessment on investigational product was done by investigator on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator's Global Assessment on Investigational Product
Percentage of participantsTramadol HCl/AcetaminophenPlacebo
Percentage of Participants With Investigator's Global Assessment on Investigational Product81.25 (72.70 to 89.80)69.88 (60.01 to 79.75)
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Chi-squared · p = 0.0917 (p-value for investigator's global assessment on investigational product at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)
SecondaryPercentage of Participants With Participants' Global Assessment on Investigational Product

Global assessment on investigational product was done by participants on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants With Participants' Global Assessment on Investigational Product
Percentage of participantsTramadol HCl/AcetaminophenPlacebo
Percentage of Participants With Participants' Global Assessment on Investigational Product76.25 (66.92 to 85.58)72.29 (62.66 to 81.92)
Statistical analysis
  • Tramadol HCl/Acetaminophen vs Placebo · Chi-squared · p = 0.5632 (p-value for participant's global assessment on investigational product at Day 29 was calculated for tramadol HCl/acetaminophen and placebo groups.)

Adverse events

Collected over Baseline up to Day 29. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol HCl/Acetaminophen—1/125 (0.8%)102/125 (81.6%)
Placebo—0/120 (0%)52/120 (43.3%)
Most frequent serious events
Most frequent serious events
EventTramadol HCl/AcetaminophenPlacebo
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1250/120
Most frequent other events
Showing 10 of 22
Most frequent other events
EventTramadol HCl/AcetaminophenPlacebo
NauseaGastrointestinal disorders45/12512/120
DizzinessNervous system disorders34/12510/120
ConstipationGastrointestinal disorders23/1254/120
VomitingGastrointestinal disorders21/1255/120
SomnolenceNervous system disorders18/1254/120
PruritusSkin and subcutaneous tissue disorders18/1254/120
DyspepsiaGastrointestinal disorders13/12512/120
HeadacheNervous system disorders11/1256/120
Decreased appetiteMetabolism and nutrition disorders6/1254/120
InsomniaPsychiatric disorders6/1250/120

Baseline characteristics

Age Continuous
Age Continuous(Years)Tramadol HCl/AcetaminophenPlaceboTotal
Mean59.93 ± 10.7260.39 ± 9.8760.16 ± 10.29
Sex: Female, Male
Sex: Female, Male(Participants)Tramadol HCl/AcetaminophenPlaceboTotal
Female9489183
Male313162
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lee JH, Lee CS; Ultracet ER Study Group. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain. Clin Ther. 2013 Nov;35(11):1830-40. doi: 10.1016/j.clinthera.2013.09.017. Epub 2013 Oct 30. PubMed 24183364 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2010
First posted
Apr 28, 2010
Start
May 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Jul 24, 2013
Last update
Jul 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01112267
Responsible party
Sponsor
First posted
Apr 28, 2010
Start date
May 2009
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jul 24, 2013
Last update
Jul 24, 2013

Study contacts

Janssen Korea, Ltd. Clinical Trial
study director · Janssen Korea, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion